TY Pennington - We love you and love what you do but please Wake Up and Get Some Facts

There is effective, non-drug help available for children and adults labelled with this diagnosis.
FMI contact us.

ADHD Fraud

"The ADHD Fraud is vital reading for everyone. The information is factual, easy to read and debunks every lie that psychiatrists have spun about childhood 'mental disorders' and the drugs used to 'treat' them. It cannot be emphasized enough the urgency with which this book needs to be broadly distributed if we are truly going to safeguard our future generation."

Dr. Baughman's long-awaited book is acclaimed for providing much needed, detailed and practical advice on how to prevent children from being labeled as victims of "ADHD" and other "mental disorders."

"Read the book and weep—for the children, and for the intellectual dishonesty that now inhabits the core of American psychiatry."

Robert Whitaker, author of Mad in America

"This book documents (how) the charlatan (quack) psychiatric profession abuses normal, healthy children with brain-destructive drugs for the unconscionable purpose of creating so-called 'mental illnesses' such as ADHD, for financial gain."

Congressman Ron Paul (M.D.)(Texas)

Read more »

Drug Gets New Warnings

First they tell you you have cancer, you accept the drugs, and wonder of wonders, look at your risk.

Oh, did they explain the risk of the drug before you signed?

If you are interested in more information about healthier options

By MATTHEW PERRONE Business Writer
Sept. 25, 2006 © 2006 The Associated Press

WASHINGTON — Federal health officials have changed the labeling of a Genentech cancer drug to include warnings of a rare brain-bleeding condition and deterioration of nasal tissue.

The Food and Drug Administration notes today on its Web site that the company's drug Avastin can possibly cause a rare brain-capillary leak syndrome that leads to headache, seizure, blindness and other visual and neurological problems. According to Genentech, less than 0.1 percent of the 60,000 patients treated with Avastin have reported the condition, which is reversible.

Genentech began reviewing safety data for Avastin after the brain-bleeding condition was described in two letters-to-the-editor published in the March issue of the "New England Journal of Medicine."

In a letter posted to the FDA's Web site today, Genentech updated physicians on the labeling changes, which also include a warning of possible nasal septum perforation.

The condition, reported in seven patients, results in a small hole between the cartilage separating the two nostrils. Side effects include bleeding and nasal discharge.

Avastin, which accounted for $1.1 billion in Genentech's revenue in fiscal 2005, is currently used with chemotherapy to treat colorectal cancer. Genentech has applied for FDA approval to use the drug in breast cancer and advanced lung cancer. Avastin works by inhibiting a protein that causes tumor growth. The company said that the negative side effects are a rare reaction to this inhibiting action.

Read more »